Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, The First Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Front Immunol. 2023 Dec 19;14:1323115. doi: 10.3389/fimmu.2023.1323115. eCollection 2023.
BACKGROUND: Cancer-associated fibroblasts (CAFs) represent the predominant stromal component within the tumour microenvironment (TME), exhibiting considerable heterogeneity and plasticity that significantly impact immune response and metabolic reprogramming within the TME, thereby influencing tumour progression. Consequently, investigating CAFs is of utmost importance. The objective of this study is to employ bibliometric analysis in order to evaluate the current state of research on CAFs and predict future areas of research and emerging trends. METHODS: Conduct a comprehensive search for scholarly publications within the Web of Science Core Collection database, encompassing the time period from January 1, 2001, to December 31, 2022. Apply VOSviewer, CiteSpace, R software and Microsoft Excel for bibliometric analysis and visualisation. RESULTS: This study involved a comprehensive analysis of 5,925 publications authored by 33,628 individuals affiliated with 4,978 institutions across 79 countries/regions. These publications were published in 908 journals, covering 14,495 keywords and 203,947 references. Notably, there was a significant increase in articles published between 2019 and 2022. China had the highest count of articles, while the United States emerged as the most frequently cited country. The primary research institutions in this field were Shanghai Jiao Tong University, Harvard University, and the University of Texas MD Anderson Cancer Center. Sotgia, Federica and Lisanti, Michael P from the University of Manchester, and Martinet, Wim from the University of Antwerp were the most prolific and highly cited authors. The journal Cancers had the highest number of publications, while Cancer Research was the most frequently cited journal. Molecular, biology, immunology, medicine and genetics were the main research disciplines in the field of CAFs. Key directions in CAFs research encompassed the study of transforming growth factor-β, Fibroblast Activation Protein, breast cancer, as well as growth and metastasis. The findings from the analysis of keyword co-occurrence and literature co-citation have revealed several emerging hotspots and trends within the field of CAFs. These include STAT3, multidrug resistance, pancreatic ductal adenocarcinoma, pan-cancer analysis, preclinical evaluation, ionizing radiation, and gold nanoparticles. CONCLUSION: Targeting CAFs is anticipated to be a novel and effective strategy for cancer treatment. This study provides a comprehensive overview of the existing research on CAFs from 2001 to 2022, utilizing bibliometric analysis. The study identified the prominent areas of investigation and anticipated future research directions, with the aim of providing valuable insights and recommendations for future studies in the field of CAFs.
背景:癌症相关成纤维细胞(CAFs)是肿瘤微环境(TME)中主要的基质成分,表现出显著的异质性和可塑性,对 TME 中的免疫反应和代谢重编程有重大影响,从而影响肿瘤的进展。因此,研究 CAFs 至关重要。本研究旨在采用文献计量分析来评估目前 CAFs 的研究状况,并预测未来的研究领域和新兴趋势。
方法:在 Web of Science 核心合集数据库中进行全面的文献检索,涵盖时间范围为 2001 年 1 月 1 日至 2022 年 12 月 31 日。使用 Vosviewer、Citespace、R 软件和 Microsoft Excel 进行文献计量分析和可视化。
结果:本研究全面分析了 5925 篇由 33628 位来自 79 个国家/地区的 4978 个机构的作者发表的文章。这些文章发表在 908 种期刊上,涵盖了 14495 个关键词和 203947 篇参考文献。值得注意的是,2019 年至 2022 年期间发表的文章数量显著增加。中国发表的文章数量最多,而美国是被引用最多的国家。该领域的主要研究机构是上海交通大学、哈佛大学和德克萨斯大学 MD 安德森癌症中心。曼彻斯特大学的 Sotgia,Federica 和 Lisanti,Michael P,以及安特卫普大学的 Martinet,Wim 是最有成果和高引用的作者。Cancers 期刊发表的文章数量最多,而 Cancer Research 期刊被引用最多。分子生物学、免疫学、医学和遗传学是 CAFs 领域的主要研究学科。CAFs 研究的主要方向包括转化生长因子-β、成纤维细胞激活蛋白、乳腺癌以及生长和转移。通过关键词共现和文献共引分析发现了 CAFs 领域的几个新兴热点和趋势。这些趋势包括 STAT3、多药耐药、胰腺导管腺癌、泛癌分析、临床前评估、电离辐射和金纳米粒子。
结论:针对 CAFs 的治疗方法有望成为一种新的有效的癌症治疗策略。本研究采用文献计量分析,对 2001 年至 2022 年 CAFs 的现有研究进行了全面概述。研究确定了突出的研究领域和预期的未来研究方向,旨在为 CAFs 领域的未来研究提供有价值的见解和建议。
Front Immunol. 2023
Front Mol Biosci. 2023-12-4
Front Biosci (Landmark Ed). 2022-8-31
J Orthop Surg Res. 2020-10-8
Front Immunol. 2023
J Cardiothorac Surg. 2024-5-11
Discov Oncol. 2025-7-17
Hum Vaccin Immunother. 2025-12
Support Care Cancer. 2025-6-24
Biochim Biophys Acta Rev Cancer. 2023-5
Mol Ther Nucleic Acids. 2023-3-10
Front Cell Infect Microbiol. 2022
Cancer Drug Resist. 2022-9-7
Front Oncol. 2022-10-19
Adv Drug Deliv Rev. 2022-10
Int J Oncol. 2022-6